Antibody Binding Specificity for Activated Dendritic Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for suitable reagents to target differentiated/activated dendritic cells (DC) in order to develop diagnostic and therapeutic agents for immunological diseases, as existing monoclonal antibodies are non-selective and lack specificity for DC subsets.
Innovation Solution
Development of binding partners and antibodies specific for DC antigens, particularly CMRF44Ab, which include peptides such as AQKYQ, capable of binding to CMRF44Ab, to create diagnostic and therapeutic agents for immunological diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies are used to target dendritic cells in allogeneic transplantation, then immune suppression is achieved, but both donor and recipient DCs are affected leading to incomplete suppression and potential GVHD
Solution Approach 1:
The patent applies local quality by developing antibodies with differential binding affinity - the antibody binds strongly to activated DCs (high expression of differentiation antigens) and weakly or not at all to immature DCs. This selective binding pattern allows the same antibody to differentially affect donor and recipient DC populations based on their activation state, thereby achieving reliable immune suppression while minimizing GVHD risk from affecting tolerant immature DCs
2Quantity of substance
If existing monoclonal antibodies are used to deplete DCs, then DC depletion is achieved, but selectivity for activated DCs is insufficient
Solution Approach 1:
The patent employs parameter changes by selecting antibodies that recognize antigens with variable expression levels - specifically differentiation antigens that are upregulated on activated DCs. The antibody's binding affinity parameter is optimized to distinguish between high-expression (activated) and low-expression (immature) states, achieving both effective DC depletion and high targeting selectivity for pathogenic activated cells
Data Source
AI summary
The present invention relates to the field of diagnostics, therapeutics and immunological reagents. More particularly, the present invention provides binding partners of antibodies specific for dendritic cell (DC) antigens. The present invention further provides diagnostic and/or therapeutic agent based on the binding partners or antibodies specific for the binding partners.